2027 Capturing the impact of Facioscapulohumeral Muscular Dystrophy (FSHD) on Health-related Quality of Life (HRQoL): a systematic review of the reliability and validity of existing self-report instruments using COSMIN Jill Carlton 1 , Philip Powell 1 , S Frances 1 , Claire Williams 1 , Anthea Sutton 1 , Jonathan Street 1 , Channa Hewamadduma 1 , Jill Carlton 1 1 University of Sheffield, Sheffield, UK Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :2027 Aims Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic muscle wasting condition causing progressive weakness
Common red flags include: Claims that a patch can replace prescription GLP-1 medications without medical oversight References to GLP-1 effects without citing human clinical research Proprietary blends that obscure ingredient amounts or mechanisms Claims that the patches contain GLP-1 active ingredients Responsible metabolic health products explain what they support, how they fit into a broader routine, and where their limitations are
J.LouJ.LokurkarI.et al (2014)
Weight Watchers: GLP-1 dosing and administration Both programs prescribe GLP-1 weight-loss medications, but their approach to dosing, titration, and follow-up differs in structure and personalization
The brand is introducing the Noom Proactive Health GLP-1 Program, which is designed to improve overall wellness while focusing on preventive health care
